Related Experiment Videos
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
Luciano Rinaldi1, P Perini, M Calabrese
1Department of Neuroscience, Multiple Sclerosis Centre, University Hospital of Padova, Padova, Italy. luceliz@libero.it
Summary
Cyclophosphamide (Cy) effectively treats aggressive multiple sclerosis (MS) by suppressing the immune system. This alkylating agent is well-tolerated, with manageable side effects, and can be used as a second-line or induction therapy.
Area of Science:
- Neuroimmunology
- Pharmacology
- Oncology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Rapidly progressive forms of MS require potent immunosuppressive therapies.
- Cyclophosphamide (Cy) has been utilized for decades in managing aggressive MS.
Purpose of the Study:
- To review the efficacy and safety of cyclophosphamide in treating multiple sclerosis.
- To outline the optimal dosing and administration protocols for cyclophosphamide in MS patients.
- To discuss the role of cyclophosphamide as a second-line or induction therapy.
Main Methods:
- Intravenous pulses of cyclophosphamide administered monthly for the first year, followed by bimonthly pulses for the second year.
- Assessment of efficacy based on relapse rates, disability accumulation, and MRI findings (gadolinium-enhancing lesions).
- Monitoring for side effects, including alopecia, nausea, vomiting, cystitis, amenorrhoea, and bladder cancer.
Main Results:
- Cyclophosphamide demonstrates effectiveness in young patients with highly active MS.
- The described pulsed protocol is generally well-tolerated.
- Common side effects are transient and reversible; severe long-term effects are rare.
Conclusions:
- Cyclophosphamide is a valuable therapeutic option for aggressive multiple sclerosis, particularly in younger individuals.
- Its use as second-line therapy for non-responders to other treatments and as induction therapy is supported.
- Careful patient selection and monitoring are essential for optimizing cyclophosphamide treatment outcomes in MS.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...